J&J’s Risperdal Consta Approved In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's Ministry of Health, Labor and Welfare April 22 approved a long-acting antipsychotic for schizophrenia, Risperdal Consta (risperidone), marketed in Japan by Janssen Pharmaceutical K.K, and manufactured by Johnson & Johnson in collaboration with Alkermes in the U.S
You may also be interested in...
Novartis Gains Four New Drugs Under Japan NHI Reimbursement; Astellas, Takeda, BMS, GSK Make Gains
TOKYO - At the recommendation of the Central Social Insurance Medical Council, known as Chuikyo in Japanese, the Ministry of Health, Labor and Welfare has listed 11 new composites for national health insurance reimbursement coverage
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).